Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.

Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW, Bertrand J; ANRS12154 Study Group.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00733-17. doi: 10.1128/AAC.00733-17. Print 2017 Dec.


CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.

Gross R, Bellamy SL, Ratshaa B, Han X, Vujkovic M, Aplenc R, Steenhoff AP, Mosepele M, Moorthy G, Zuppa AF, Strom BL, Bisson GP.

AIDS. 2017 Sep 24;31(15):2107-2113. doi: 10.1097/QAD.0000000000001593.


Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.


Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.

Zhou Y, Ingelman-Sundberg M, Lauschke VM.

Clin Pharmacol Ther. 2017 Oct;102(4):688-700. doi: 10.1002/cpt.690. Epub 2017 May 26.


CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.

Bolton Moore C, Capparelli EV, Samson P, Bwakura-Dangarembizi M, Jean-Philippe P, Worrell C, Heckman B, Purdue L, Spector SA, Benns A, Borkowsky W, Loftis A, Hawkins E, Wallis C, Chadwick EG; IMPAACT P1070 team.

AIDS. 2017 May 15;31(8):1129-1136. doi: 10.1097/QAD.0000000000001463.


The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, Scarsi KK.

Clin Pharmacol Ther. 2017 Sep;102(3):529-536. doi: 10.1002/cpt.667. Epub 2017 May 30.


Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW.

Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.


Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.

Carr DF, Bourgeois S, Chaponda M, Takeshita LY, Morris AP, Castro EM, Alfirevic A, Jones AR, Rigden DJ, Haldenby S, Khoo S, Lalloo DG, Heyderman RS, Dandara C, Kampira E, van Oosterhout JJ, Ssali F, Munderi P, Novelli G, Borgiani P, Nelson MR, Holden A, Deloukas P, Pirmohamed M.

J Antimicrob Chemother. 2017 Apr 1;72(4):1152-1162. doi: 10.1093/jac/dkw545.


Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?

Rhead R, Masimirembwa C, Cooke G, Takaruza A, Nyamukapa C, Mutsimhi C, Gregson S.

PLoS One. 2016 Dec 14;11(12):e0167852. doi: 10.1371/journal.pone.0167852. eCollection 2016.


Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

Nwogu JN, Ma Q, Babalola CP, Adedeji WA, Morse GD, Taiwo B.

AIDS Res Treat. 2016;2016:2587094. Epub 2016 Sep 29. Review.


Insights into CYP2B6-mediated drug-drug interactions.

Hedrich WD, Hassan HE, Wang H.

Acta Pharm Sin B. 2016 Sep;6(5):413-425. Epub 2016 Aug 9. Review.


Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.


Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.

Leger P, Chirwa S, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW.

Pharmacogenet Genomics. 2016 Oct;26(10):473-80. doi: 10.1097/FPC.0000000000000238.


Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Shah A, Gangwani MR, Chaudhari NS, Glazyrin A, Bhat HK, Kumar A.

Neurotox Res. 2016 Nov;30(4):677-697. Epub 2016 Jun 30. Review.


Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV.

Hui KH, Lee SS, Lam TN.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):182-91. doi: 10.1002/psp4.12067. Epub 2016 Apr 6.


Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

Nightingale S, Chau TT, Fisher M, Nelson M, Winston A, Else L, Carr DF, Taylor S, Ustianowski A, Back D, Pirmohamed M, Solomon T, Farrar J, Törok ME, Khoo S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4511-8. doi: 10.1128/AAC.00280-16. Print 2016 Aug.


Individualization of antiretroviral therapy--pharmacogenomic aspect.

Dalal B, Shankarkumar A, Ghosh K.

Indian J Med Res. 2015 Dec;142(6):663-74. doi: 10.4103/0971-5916.174549. Review.


Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.

Schackman BR, Haas DW, Park SS, Li XC, Freedberg KA.

Pharmacogenomics. 2015 Dec;16(18):2007-18. doi: 10.2217/pgs.15.142. Epub 2015 Nov 26.


Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation.

El-Serafi I, Afsharian P, Moshfegh A, Hassan M, Terelius Y.

PLoS One. 2015 Nov 6;10(11):e0141979. doi: 10.1371/journal.pone.0141979. eCollection 2015.


Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.

Mhandire D, Lacerda M, Castel S, Mhandire K, Zhou D, Swart M, Shamu T, Smith P, Musingwini T, Wiesner L, Stray-Pedersen B, Dandara C.

OMICS. 2015 Sep;19(9):553-62. doi: 10.1089/omi.2015.0104.

Supplemental Content

Support Center